SomaLogic

SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company was founded by Larry Gold in 2000 and is headquartered in Boulder, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

SomaLogic reports mixed Q4 results, eyes growth through innovation

SomaLogic navigated a mixed financial performance in Q4 2022, focusing on cost management.
The company is strengthening its position in the life sciences sector with innovative products.
Challenges lie in leadership transitions and balancing expenses with growth investments.
Opportunities abound in strategic collaborations, product launches, and market expansion.

SomaLogic reports Q1 revenue growth amid margin challenges

SomaLogic's Q1 performance reflects revenue growth initiatives amidst financial challenges.
Strategic partnerships, expansion plans, and product launches position the company for future growth.
Addressing margin issues and optimizing expenses are critical for achieving profitability and meeting revenue targets.

SomaLogic reports robust Q2 revenue growth, eyes international partnerships

SomaLogic's Q2 2023 performance reflects strong revenue growth and improved cost management, yet challenges persist in achieving profitability.
Strategic strengths include experienced leadership, international expansion, and partnerships driving growth opportunities in the life sciences sector.
Maintaining operational rigor, enhancing margins, and leveraging cash reserves position SomaLogic for sustainable growth and market leadership.

SomaLogic reports revenue growth and strategic merger for future growth

SomaLogic's Q3 2023 performance showed revenue growth and cost management improvements, with a strong cash position. Strategic partnerships and merger offer growth opportunities.
Challenges include revenue decline on a GAAP basis and ongoing EBITDA losses. Opportunities lie in new indications, geographic expansion, and biopharma performance drivers.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOULDER, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) --  SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended June 30, 2022.

SomaLogic Reports Second Quarter 2022 Financial Results

BOULDER, Colo. and SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced it entered into an agreement to acquire Palamedrix, Inc., an innovator in DNA nanotechnology. Palamedrix provides deep scientific and engineering expertise, miniaturization technology and enhanced ease-of-use capabilities that SomaLogic intends to leverage as it develops the next generation of the SomaScan® Assay. The acquisition brings two leading technologies together which SomaLogic believes will accelerate SomaScan Platform utilization in global biopharma and academic markets, as well as the emerging proteomic diagnostics space.

SomaLogic acquires DNA nanotechnology leader Palamedrix to develop the next-generation SomaScan® Assay

BOULDER, Colo. , July 25, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding audio webcast beginning at 4:30 p.m. ET.

SomaLogic to Announce Second Quarter 2022 Financial Results

SomaLogic, Inc. (NASDAQ:SLGC ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Marissa Bych - IR, Gilmartin Group LLC Roy Smythe - CEO Shaun Blakeman - CFO Stephen Williams - CMO Conference Call Participants Brandon Couillard - Jefferies Daniel Brennan - Cowen Kyle Mikson - Canaccord Dan Arias - Stifel Operator Good day ladies and gentlemen, and thank you for standing by. Welcome to the SomaLogic's First Quarter 2022 Earnings Conference Call.

SomaLogic, Inc. (SLGC) CEO Roy Smythe on Q1 2022 Results - Earnings Call Transcript

BOULDER, Colo., April 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. ET.

SomaLogic to Announce First Quarter 2022 Financial Results

SomaScan® platform study utilizing 32,000 samples showed a 27-protein test is a uniquely superior surrogate for cardiovascular outcomes SomaScan® platform study utilizing 32,000 samples showed a 27-protein test is a uniquely superior surrogate for cardiovascular outcomes

Major journal publishes landmark proteomics study demonstrating development of an unprecedented new clinical cardiovascular risk test

SomaLogic offers a pioneering platform for the study and engineering of various proteins, which lends itself to a large number of diseases giving the company a large pipeline.

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Twist Bioscience Corp

Cathie Wood's Ark Invest may have had a disappointing 2021, but the fund's purchases/liquidations are always watched keenly by investors. On Friday, ETFs managed by Ark Invest picked up chunks of shares of two healthcare companies.

Know The 2 Healthcare Companies Cathie Wood's Ark Invest Bought On Friday

SomaLogic, Inc. (SLGC) CEO Roy Smythe on Q4 2021 Results Earnings Call Transcript

BOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter and year ended December 31, 2021.

SomaLogic Reports Fourth Quarter and Full Year 2021 Financial Results

BOULDER, Colo., March 01, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 29, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

SomaLogic to Announce Fourth Quarter and Full Year 2021 Financial Results

B2Gold

Clean Energy Fuels

Helix Energy Solutions Group

Skillsoft

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Buy-Rated Stocks Trading Under $10 With Incredible Upside Potential

BOULDER, Colo., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the Cowen 42nd Annual Health Care Conference.

SomaLogic to Participate in the Cowen 42nd Annual Health Care Conference

SomaLogic (SLGC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for SomaLogic (SLGC)

BOULDER, Colo., Feb. 04, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual analyst and investor meeting today, February 4th, 2022, from 10:00 a.m. to approximately 1:00 p.m. Eastern Time. The event is intended to highlight recent corporate updates, technical specifications and capabilities of the SomaScan platform, and various applications across life science tools and clinical diagnostics. SomaLogic management will be joined by leading experts and partners to discuss several ongoing initiatives demonstrating the vast potential for proteomics to deliver meaningful insights that can positively impact human health.

SomaLogic Provides 2022 Revenue Guidance in Conjunction with Analyst and Investor Meeting

BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following virtual investor conferences.

SomaLogic to Participate in Upcoming Investor Conferences

Data will be available to researchers studying a wide range of disease states Data will be available to researchers studying a wide range of disease states

SomaLogic to provide 105 million protein measurements from 15,000 samples as part of the Multi-Ethnic Study of Atherosclerosis (MESA) Study

BOULDER, Colo., Jan. 10, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Adam Taich has joined the company as the Chief Business Officer.

SomaLogic Announces Appointment of Adam Taich as Chief Business Officer

Illumina

Illumina's (ILMN) collaboration with SomaLogic will boost the fast-growing high throughput sector of the proteomics market to aid research in biology and disease.

Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics

Graphite Bio

Two public companies made the BioSpace list of the 30 most promising North American life sciences startups. SomaLogic Inc. ( SLGC , Financial) and Graphite Bio Inc. ( GRPH , Financial) are included in the NextGen Bio “Class of 2022.

SomaLogic, Graphite Bio Make List of Most Promising Life Sciences Companies

Co-developed and co-branded products to combine market-leading proteomic and genomic analysis platforms Co-developed and co-branded products to combine market-leading proteomic and genomic analysis platforms

SomaLogic announces exclusive partnership with Illumina to develop sequencing-based proteomic solutions

BOULDER, Colo., Dec. 30, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

SomaLogic to Participate in the 40th Annual J.P. Morgan Healthcare Conference

BOULDER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that Steve Mermelstein joined the company as Senior Vice President of Corporate Strategy, Development and Mergers and Acquisitions (M&A).

SomaLogic Announces Appointment of Steven Mermelstein as Senior Vice President of Corporate Strategy, Development and Mergers and Acquisitions

SomaLogic, Inc. (SLGC) CEO Roy Smythe on Q3 2021 Results - Earnings Call Transcript

BOULDER, Colo., Nov. 15, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today reported financial results for the quarter ended September 30, 2021.

News for SomaLogic Stock (SLGC)